11-Dehydro-thromboxane B2

11-Dehydro-thromboxane B2 is a stable terminal metabolite of thromboxane A2 and an agonist of the CRTH2 receptor. 11-Dehydro-TXB2 activates human eosinophils, basophils, and CRTH2-transfected BaF/3 cells through a pertussis toxin-insensitive G protein-PLC pathway, inducing intracellular calcium mobilization, morphological changes, and chemotaxis, but does not affect platelet aggregation. 11-Dehydro-thromboxane B2 is involved in thrombosis and promotes eosinophil recruitment to the lungs in allergic inflammation, and its urinary levels are used to assess the inhibitory effect of Aspirin (HY-14654) on thromboxane production. 11-Dehydro-TXB2 serves as a biomarker for research related to asthma, atopic rhinitis, nephropathy, and coronary artery disease^[1][2][3]. In Vitro:11-Dehydro-thromboxane B2 (30 nM-10 μM; 4 min) induces concentration-dependent morphological changes in human eosinophils and basophils, with an EC₅₀ of 300 nM^[1].
11-Dehydro-thromboxane B2 (10 μM; 4-6 min) induces calcium influx in human eosinophils, and this calcium influx is primarily derived from intracellular stores, while also producing cross-desensitization of PGD₂-mediated calcium responses, confirming that both share the same receptor^[1].
11-Dehydro-thromboxane B2 (1-5 h) induces chemotaxis in human eosinophils and hCRTH2-transfected BaF/3 cells^[1].
11-Dehydro-thromboxane B2 induces morphological changes in human eosinophils that are not inhibited by pertussis toxin and involve phospholipase C activation, consistent with the signaling pathway mediated by PGD₂ through CRTH2^[1].
11-Dehydro-thromboxane B2 (4-5 min)-induced morphological changes in human eosinophils are inhibited by the CRTH2/TP antagonist Ramatroban (HY-B0745), but not by the selective TP antagonist SQ29,548 (HY-108972), confirming that this process is mediated by CRTH2^[1].
11-Dehydro-thromboxane B2 exhibits no CRTH2 antagonistic activity at its threshold activation concentration, confirming that it is a full CRTH2 agonist^[1].
11-Dehydro-thromboxane B2 (10 μM; 2-5 min) does not interact with pro-aggregatory thromboxane TP receptors or anti-aggregatory prostaglandin DP receptors in human platelets, exhibiting no agonist or antagonist activity^[1].